论文部分内容阅读
HMGA2是一种结构性转录因子,在肺癌等多种肿瘤中过表达,是肿瘤治疗的候选靶点之一。RNAi技术作为一种经济、有效的基因沉默工具,是肿瘤治疗的新手段。本文以Hmga2基因为靶点,设计并合成了5条siRNA(HMGA2 siRNA1-5),通过MTT、平板克隆、Transwell、流式细胞术等手段,研究其对肺癌细胞(NCI-H446和A549)增殖、克隆形成、迁移和凋亡等能力的影响。结果表明,HMGA2 siRNA1、3、5对肺癌细胞的各项性能具有不同程度的影响,其中HMGA2 siRNA5尤为明显。HMGA2 siRNA5主要通过沉默Hmga2基因影响细胞性能,与其干扰素效应关系不大。本文筛选获得了可有效沉默Hmga2基因的siRNA,其在体外具有良好的抗肺癌活性,是具有一定潜力的肿瘤基因治疗候选药物。
HMGA2 is a structural transcription factor that is overexpressed in many tumors such as lung cancer and is one of the candidate targets for cancer therapy. As an economical and effective gene silencing tool, RNAi technology is a new method of cancer treatment. In this paper, five siRNAs (HMGA2 siRNA1-5) were designed and synthesized based on the Hmga2 gene. The proliferation of lung cancer cells (NCI-H446 and A549) was studied by MTT, plate clone, Transwell and flow cytometry , Clonal formation, migration and apoptosis. The results showed that HMGA2 siRNA1,3,5 had different effects on various properties of lung cancer cells, especially HMGA2 siRNA5. HMGA2 siRNA5 mainly affects the cell performance by silencing the Hmga2 gene, which has little to do with its interferon effect. This study screened Hmga2 gene can effectively silence the siRNA, which in vitro has good anti-lung cancer activity, is a potential candidate for gene therapy of cancer.